Sermorelin

Overview

Sermorelin is a synthetic 29-amino acid peptide representing the first 29 amino acids of the 44-amino acid human growth hormone-releasing hormone (GHRH). This truncated sequence retains full biological activity at the GHRH receptor, making Sermorelin functionally equivalent to endogenous GHRH for research purposes.

Mechanism of Action

Sermorelin binds to GHRH receptors on pituitary somatotroph cells, stimulating the natural synthesis and pulsatile release of growth hormone. Unlike exogenous GH administration, sermorelin preserves the negative feedback mechanisms that regulate GH production, maintaining physiological pulsatile patterns and preventing supraphysiological levels.

Research Context

Sermorelin has a long history of clinical use and research, with FDA approval history for GH deficiency diagnostic testing and pediatric GH stimulation. It is often considered the "gold standard" GHRH analog for research due to its extensive safety and efficacy data.

Key Research Areas

Considerations for Researchers

The wide price range reflects differing purities and vendor markup strategies. Sermorelin has a short half-life (10-20 minutes), requiring more frequent administration than modified analogs. Store lyophilized at -20C.